The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
 
Dagmar Hess
Stock and Other Ownership Interests - Roche/Novartis; Roche/Novartis (I)
 
Katrine Fladeland Iversen
Stock and Other Ownership Interests - Novo Nordisk (I)
Research Funding - Anaveon; Genentech; Genmab
 
Maria-Victoria Mateos
Honoraria - Abbvie/Genentech; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pfizer; Regeneron; Roche/Genentech; Takeda
 
Thomas Pabst
No Relationships to Disclose
 
Laura Rosiñol
Honoraria - Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Sanofi
 
Jana Kovacikova
Employment - Anaveon
 
Sangeeta Jethwa Schnetzler
Employment - Anaveon